Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
MICHAEL P. COOREMAN, SVEN FRANCQUE, LUCILE DZEN, PHILIPPE HUOT-MARCHAND, JEAN L. JUNIEN, PIERRE BROQUA, MANAL F. ABDELMALEK
Publikováno v:
Diabetes. 71
Lanifibranor therapy resulted in both NASH resolution and fibrosis reduction in the phase 2b NATIVE study in patients with non-cirrhotic NASH, compared to placebo. PPAR signaling is involved in common pathways of NASH and type 2 diabetes (T2D) . We e
Autor:
Ying Wang, Anna Mae Diehl, Ricardo Henao, Manal F. Abdelmalek, Keri A. Seymour, Ranjan Sudan, Matthew J Crowley, Cynthia D. Guy, Anastasia-Stefania Alexopoulos, Dana Portenier, Andrea D. Coviello
Publikováno v:
Diabetes. 69
T2DM increases risk for advanced fibrosis in NAFLD, however little is known about the impact of glycemic control on fibrosis severity. Objective: To assess whether glycemic control is associated with severity of fibrosis in NAFLD. Methods: We utilize
Autor:
Naim Alkhouri, Andrea D. Coviello, Manal F. Abdelmalek, Eduardo B. Martins, Gerardo Rodriguez
Publikováno v:
Diabetes. 69
Introduction: In mice, C-C motif chemokine receptor (CCR)5 deletion protects against insulin resistance, hepatic steatosis, and glucose intolerance. We aimed to characterize the metabolic effects of cenicriviroc (CVC), a potent CCR2/5 inhibitor, in t
Autor:
Bill Tan, Eduardo B. Martins, Andrea D. Coviello, Naim Alkhouri, Ralph W. Charlton, Manal F. Abdelmalek
Publikováno v:
Diabetes. 68
Background: The treatment landscape of nonalcoholic steatohepatitis (NASH) is changing rapidly; drug safety is key as most patients will need long-term treatment. Cenicriviroc (CVC) is an oral antagonist of C-C chemokine receptors 2/5 in Phase 3 deve
Autor:
Ralph W. Charlton, Manal F. Abdelmalek, Eduardo B. Martins, Andrea D. Coviello, Henrik Landgren, Naim Alkhouri
Publikováno v:
Diabetes. 68
Background: Nonalcoholic steatohepatitis (NASH) is considered the hepatic manifestation of type 2 diabetes and can progress to advanced fibrosis (AF), associated with significant increase in morbidity and mortality. CVC is an oral C-C chemokine recep
Autor:
N. Afdhal, Andrew J. Muir, Rob Myers, B. Mccolgan, Zachary Goodman, Eric Lawitz, Stephen Caldwell, S. Djedjos, Stephen A. Harrison, Jaime Bosch, Deyuan Jiang, Vlad Ratziu, Arun J. Sanyal, Mitchell L. Shiffman, Manal F. Abdelmalek, Reem Ghalib, Raul Aguilar Schall
Publikováno v:
Diabetes. 68
Background: Diabetes is a risk factor for advanced fibrosis due to NASH, but the effect of diabetes on disease progression is not well-characterized. Here, we describe clinical outcomes for patients with and without diabetes in two negative, randomiz
Autor:
Ransi M. Somaratne, Stephen J. Rossi, Stephen A. Harrison, Mark Jaros, Manal F. Abdelmalek, Lei Ling, Alex M. DePaoli
Publikováno v:
Diabetes. 67
Background: NGM282 is an engineered variant of human FGF-19 that retains bile acid and metabolic regulatory activities while eliminating the tumorigenic effects of FGF-19. Multiple preclinical models showed improvements in NASH liver histology simila